Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXLNASDAQ:CRONNYSE:HNGRNASDAQ:MCRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$8.55+3.6%$8.93$3.51▼$14.44$704.32M0.821.22 million shs735,040 shsCRONCronos Group$2.05+3.5%$1.82$1.60▼$3.14$790.08M1.061.33 million shs2.92 million shsHNGRHanger$18.72$18.70$13.42▼$22.67$732.38M1.28356,429 shsN/AMCRBSeres Therapeutics$7.88+11.8%$11.52$6.64▼$30.60$68.81M2.89147,385 shs99,891 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+3.64%-4.04%-3.50%+3.14%+124.41%CRONCronos Group+3.54%+7.89%+17.14%+4.06%-25.99%HNGRHanger0.00%0.00%0.00%0.00%0.00%MCRBSeres Therapeutics+11.77%-14.63%-33.28%-50.69%-61.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.8256 of 5 stars3.71.00.04.72.70.80.6CRONCronos Group1.4724 of 5 stars2.04.00.00.02.50.01.3HNGRHanger1.188 of 5 stars0.00.00.04.40.01.71.9MCRBSeres Therapeutics3.2414 of 5 stars2.92.00.04.61.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.33Buy$44.00414.62% UpsideCRONCronos Group 0.00N/A$3.5070.73% UpsideHNGRHanger 0.00N/AN/AN/AMCRBSeres Therapeutics 1.80Reduce$73.67834.86% UpsideCurrent Analyst Ratings BreakdownLatest HNGR, MCRB, AVXL, and CRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.004/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.003/31/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/20/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/14/2025MCRBSeres TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $15.002/18/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ACRONCronos Group$117.62M6.72N/AN/A$2.87 per share0.71HNGRHanger$1.12B0.65$1.88 per share9.98$2.85 per share6.57MCRBSeres Therapeutics$126.33M0.54N/AN/A($0.35) per share-22.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%5/13/2025 (Estimated)CRONCronos Group-$73.96M$0.10N/A68.331.74-42.65%-2.56%-2.47%N/AHNGRHanger$41.98M$0.9519.7115.60N/A3.17%35.72%4.00%N/AMCRBSeres Therapeutics-$113.72M-$4.60N/AN/AN/AN/AN/A-55.08%N/ALatest HNGR, MCRB, AVXL, and CRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16N/AN/AN/AN/AN/A5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AHNGRHangerN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A9.459.45CRONCronos GroupN/A24.2423.05HNGRHanger3.711.230.85MCRBSeres TherapeuticsN/A1.121.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%CRONCronos Group8.71%HNGRHanger79.17%MCRBSeres Therapeutics59.34%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%CRONCronos Group7.30%HNGRHanger4.36%MCRBSeres Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.37 million75.71 millionOptionableCRONCronos Group450385.41 million356.14 millionOptionableHNGRHanger5,20039.12 million37.42 millionOptionableMCRBSeres Therapeutics3308.73 million162.03 millionOptionableHNGR, MCRB, AVXL, and CRON HeadlinesRecent News About These CompaniesStockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to HoldMay 11 at 3:53 AM | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.comMay 11 at 3:53 AM | marketbeat.comSeres Therapeutics' (MCRB) Neutral Rating Reaffirmed at Chardan CapitalMay 10 at 8:06 AM | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call TranscriptMay 9, 2025 | insidermonkey.comChardan Capital Downgrades Seres Therapeutics (MCRB)May 9, 2025 | msn.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Given Average Recommendation of "Hold" by AnalystsMay 8, 2025 | americanbankingnews.comSeres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comSeres Therapeutics reports Q1 EPS $3.75, consensus $1.97May 7, 2025 | msn.comSeres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 7, 2025 | globenewswire.comSeres Therapeutics Q1 2025 Earnings PreviewMay 6, 2025 | msn.comWhy Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 5.09%May 6, 2025 | aaii.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of "Hold" by BrokeragesMay 5, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50-Day Moving Average - Here's What HappenedMay 4, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.comMay 3, 2025 | marketbeat.comSeres Therapeutics (MCRB) Projected to Post Quarterly Earnings on WednesdayMay 2, 2025 | marketbeat.comSeres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune DiseasesApril 29, 2025 | globenewswire.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Sees Large Decrease in Short InterestApril 28, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Hits New 12-Month Low - Here's What HappenedApril 25, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Shares Up 10% - Still a Buy?April 24, 2025 | marketbeat.comPetri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock splitApril 24, 2025 | bizjournals.comSeres Therapeutics trading resumesApril 24, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHNGR, MCRB, AVXL, and CRON Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$8.55 +0.30 (+3.64%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$8.55 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Cronos Group NASDAQ:CRON$2.05 +0.07 (+3.54%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$2.04 -0.01 (-0.49%) As of 05/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Hanger NYSE:HNGRHanger, Inc. provides orthotic and prosthetic (O&P) services in the United States. It operates in two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and offers payor network contracting services to other O&P providers. The Products & Services segment engages in the distribution of various O&P parts, componentry, and devices to independent O&P providers; development of specialized rehabilitation technologies; and provision of evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2021, the company operated approximately 760 patient care clinics and 115 satellite locations in 47 states and the District of Columbia. It also distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings. The company was formerly known as Hanger Orthopedic Group, Inc. and changed its name to Hanger, Inc. in June 2012. Hanger, Inc. was founded in 1861 and is headquartered in Austin, Texas.Seres Therapeutics NASDAQ:MCRB$7.88 +0.83 (+11.77%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$7.55 -0.33 (-4.18%) As of 04:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
